Baseline Laboratory Assessment Before initiating GHK-Cu therapy, obtain: Serum copper level (normal range: 70 to 140 mcg/dL) Ceruloplasmin (normal range: 20 to 35 mg/dL) 24-hour urine copper (to exclude copper overload states) Hepatic function panel (AST, ALT, alkaline phosphatase, total bilirubin) Complete blood count with differential Wound photography and planimetric measurement (length, width, area) Wound culture if signs of infection are present Patients with Wilson disease, known copper storage disorders, or hepatic cirrhosis should not receive exogenous copper peptides [13]
Topical Application: In some pre-clinical studies, BPC-157 has been applied topically as a thin layer of cream at the site of injury, demonstrating efficacy in wound healing
The results demonstrated a significant increase in the abundance of beneficial butyrate-producing bacteria, such as Faecalibacterium and Anaerobutyricum , in the gut microbiota of the intervention group
The compounding pharmacy decides what is actually in the vial: a 503A or 503B partner is the single most important detail patients never ask about
People are injecting substances from suppliers they found on Google into their bodies with no independent verification of what's actually in the vial